BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/22/2022 10:47:33 AM | Browse: 18 | Download: 25
Publication Name World Journal of Clinical Oncology
Manuscript ID 77472
Country/Territory Spain
2022-05-09 01:28
Peer-Review Started
2022-05-09 01:30
To Make the First Decision
Return for Revision
2022-06-16 10:43
2022-07-06 22:52
Second Decision
2022-08-29 03:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-08-31 04:31
Articles in Press
2022-08-31 04:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2022-09-14 06:40
Publish the Manuscript Online
2022-09-22 06:32
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Letter to the Editor
Article Title Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
Manuscript Source Unsolicited Manuscript
All Author List Carlos Aguado, Unai Jiménez Maestre and Xabier Mielgo-Rubio
Funding Agency and Grant Number
Corresponding Author Carlos Aguado, MD, Consultant Physician-Scientist, Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Calle del Prof Martín Lagos, Madrid 28040, Spain. carlos.aguado84@gmail.com
Key Words Neoadjuvant; Immunotherapy; NSCLC; Perioperative; Checkmate-816; nivolumab; Chemo-immunotherapy
Core Tip Recent data from a phase 3 trial show that the addition of immunotherapy to neoadjuvant chemotherapy in patients with non-small-cell lung cancer (NSCLC) improves pathologic complete response and event-free survival. This is the first positive phase 3 trial in this setting, although several other phase 3 studies are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC. We describe the results of the CheckMate-816 phase 3 trial, which found that neoadjuvant chemoimmunotherapy was superior to chemotherapy alone. We also briefly review the main phase 3 studies currently underway to evaluate the role of immunotherapy in the perioperative setting of NSCLC.
Publish Date 2022-09-22 06:32
Citation Aguado C, Maestre UJ, Mielgo-Rubio X. Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast. World J Clin Oncol 2022; 13(9): 758-761
URL https://www.wjgnet.com/2218-4333/full/v13/i9/758.htm
DOI https://dx.doi.org/10.5306/wjco.v13.i9.758
Full Article (PDF) WJCO-13-758.pdf
Full Article (Word) WJCO-13-758.docx
Manuscript File 77472_Auto_Edited-LM.docx
Answering Reviewers 77472-Answering reviewers.pdf
Audio Core Tip 77472-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 77472-Conflict-of-interest statement.pdf
Copyright License Agreement 77472-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 77472-Language certificate.pdf
Peer-review Report 77472-Peer-review(s).pdf
Scientific Misconduct Check 77472-Bing-Liu JH-2.jpg
Scientific Misconduct Check 77472-CrossCheck.jpg
Scientific Editor Work List 77472-Scientific editor work list.pdf